Howard Berman, Coya Therapeutics CEO
November 21, 2022 11:37 AM EST
Financing
R&D

Six-per­son ALS biotech wants to go pub­lic — but it’s al­so piv­ot­ing from ear­li­er plans

Lei Lei Wu

News Reporter

With an S-1 fil­ing with the SEC on Fri­day, reg­u­la­to­ry T cell op­er­a­tion Coya Ther­a­peu­tics fore­shad­owed its plans to get on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times